Running Oak Capital LLC raised its stake in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) by 7.5% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 208,331 shares of the medical equipment provider’s stock after acquiring an additional 14,449 shares during the quarter. Running Oak Capital LLC’s holdings in Boston Scientific were worth $9,094,000 at the end of the most recent reporting period.
Several other institutional investors have also modified their holdings of the stock. Clal Insurance Enterprises Holdings Ltd acquired a new position in shares of Boston Scientific during the 1st quarter worth about $28,000. Cassaday & Co Wealth Management LLC purchased a new position in Boston Scientific in the 1st quarter valued at about $32,000. Measured Wealth Private Client Group LLC boosted its holdings in Boston Scientific by 244.9% in the 1st quarter. Measured Wealth Private Client Group LLC now owns 545 shares of the medical equipment provider’s stock worth $34,000 after buying an additional 387 shares during the last quarter. Kelleher Financial Advisors acquired a new stake in Boston Scientific in the 2nd quarter worth about $25,000. Finally, Nvwm LLC increased its stake in Boston Scientific by 526.2% during the 3rd quarter. Nvwm LLC now owns 645 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 542 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of equities analysts have commented on BSX shares. Argus cut Boston Scientific from a “buy” rating to a “hold” rating in a report on Friday, July 31st. Canaccord Genuity Group dropped their price target on Boston Scientific from $66.00 to $48.00 and set a “buy” rating for the company in a research report on Thursday, October 29th. Needham & Company LLC decreased their price objective on Boston Scientific from $57.00 to $48.00 and set a “buy” rating on the stock in a report on Wednesday, October 28th. Robert W. Baird upped their target price on shares of Boston Scientific from $50.00 to $51.00 and gave the stock an “outperform” rating in a report on Thursday, October 29th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Boston Scientific in a research report on Friday, October 2nd. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Boston Scientific presently has an average rating of “Moderate Buy” and an average price target of $61.43.
Get Our Latest Analysis on Boston Scientific
Boston Scientific Trading Up 2.9%
NYSE BSX opened at $44.00 on Tuesday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.36 and a quick ratio of 0.74. The stock has a market capitalization of $63.78 billion, a P/E ratio of 18.64, a PEG ratio of 1.36 and a beta of 0.60. The firm’s 50-day moving average is $44.26 and its two-hundred day moving average is $55.46. Boston Scientific Corporation has a 12 month low of $39.57 and a 12 month high of $105.65.
Boston Scientific (NYSE:BSX – Get Free Report) last released its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.73. Boston Scientific had a net margin of 16.62% and a return on equity of 18.61%. The business had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $5.09 billion. During the same period in the previous year, the firm earned $0.75 EPS. The business’s revenue was up 1.4% on a year-over-year basis. On average, sell-side analysts anticipate that Boston Scientific Corporation will post 3.17 earnings per share for the current year.
About Boston Scientific
Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts.
Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.
Boston Scientific serves healthcare providers and patients around the world.
Featured Stories
- Five stocks we like better than Boston Scientific
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX – Free Report).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
